Insider Transactions in Q3 2024 at Bluebird Bio, Inc. (BLUE)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
34,780
-8.48%
|
$0
$0.53 P/Share
|
|
Sep 30
2024
|
Andrew Obenshain President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+24.07%
|
-
|
|
Sep 30
2024
|
Thomas J Klima |
SELL
Open market or private sale
|
Direct |
1,006
-0.59%
|
$0
$0.53 P/Share
|
|
Sep 30
2024
|
Thomas J Klima |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+22.62%
|
-
|
|
Sep 30
2024
|
Michael Cloonan |
BUY
Grant, award, or other acquisition
|
Direct |
37,350
+50.0%
|
-
|
|
Sep 30
2024
|
O. James Sterling Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Sep 30
2024
|
Joseph Vittiglio Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+34.53%
|
-
|
|
Sep 30
2024
|
Richard A Colvin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+22.9%
|
-
|